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1. Introduction
The identification of  melanoma-associated antigens,  the  isolation of  tumor  infiltrating  T
cells from melanoma lesions, and the significant progress in engineering redirected T cells
has favored the development of various strategies in the adoptive immunotherapy of mel‐
anoma. Recent trials in adoptive cell  therapy (ACT) have achieved spectacular results in
inducing remission in advanced stages of the disease, although produced on-target off-tu‐
mor  toxicities,  emphasizing the  tremendous potential  benefit  of  harnessing the  immune
system for fighting the disease.  Moreover,  the identification of so-called melanoma stem
cells  along  with  strategies  for  selectively  eliminating  subsets  of  melanoma cells  implies
that there is a need for redefining therapeutic targets in melanoma. This review discusses
current  challenges  in  the  rational  design of  adoptive  cell  therapy to  target  “the beating
heart” of melanoma.
1.1. Advanced stages of melanoma resist conventional therapeutic regimens
Surgical resection of tumor lesions in early stages of the disease is the curative option for
combating melanoma; a 10-year-survival rate of 75 - 85% can be achieved for melanoma in
stage I or II. However, melanoma in stage III or IV is still associated with low survival rates
of less than 1 year upon diagnosis [1]. Despite the development of novel drugs and major
improvements in therapeutic regimens, significant responses were only achieved in prede‐
fined groups and of short duration. Treatment with the chemotherapeutic drug dacarbazine
(DTIC) and vemurafenib, an inhibitor of mutated BRAF, produced a median progression-
free survival of 64% with dacarbazine, respectively 84% with vemurafenib of approximately
6 months [2-4]. The biology of melanoma and the heterogeneity of malignant cells are
thought to be responsible for this unsatisfactory situation. First, melanoma cells can persist
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for long periods of time in a “dormant” stage without any progression in tumor formation
[5]. Second, melanoma cells can disseminate early into distant organs including the brain
forming micro-metastases, which are small in cell numbers and frequently beyond the de‐
tection limit of current imaging procedures [6, 7]. Third, many melanoma cells are notori‐
ously resistant to chemo- and radiation therapy [8-10], making alternative strategies in
tumor cell elimination necessary.
Therefore,  in  more  progressed  stages  of  the  disease  the  recruitment  of  the  cellular  im‐
mune defense to eliminate cancer cells is thought to be an alternative. Administration of
high  dose  interleukin-2  (IL-2)  [11]  and  anti-cytotoxic  T-lymphocyte-associated  antigen-4
(CTLA-4) antibody [12] as well as interferon (IFN) α-2b prolongs the disease-free survival
although at a relatively low response rate and without being curative over time [13, 14].
However,  these  and  other  observations  imply  that  activation  or  modulation  of  the  pa‐
tient’s immune response may be effective in the treatment of melanoma. A number of ap‐
proaches  for  enhancing  the  immune  cell  response  against  melanoma  are  currently
explored with some success. In particular, the adoptive transfer of autologous T cells iso‐
lated from melanoma lesions and expanded to large numbers ex vivo has produced en‐
couraging  phase  II  results  [15,  16].  The  administration  of  patient’s  blood  T  cells
engineered with defined specificity for melanoma-associated antigens are additionally be‐
ing explored in a number of trials. In this review, we summarize evidence for the potency
of adoptive T cell therapy in the treatment of melanoma and discuss current challenges in
achieving  long-term  remission.  Upcoming  strategies  in  selective  targeting  cancer  stem
cells are also discussed.
2. Adoptive cell therapy can successfully fight melanoma
Melanoma  can  trigger  a  curative  immune  response;  this  conclusion  is  drawn  from  the
clinical observation of spontaneous and complete melanoma regressions and of the higher
frequency of melanomas among immune compromised patients [17, 18]. More direct evi‐
dence  for  the  immune cell  control  of  melanoma growth was obtained by the  treatment
with high dose IL-2, which produces an objective response rate of 16%. Indeed, some of
the patients receiving thus treatment exhibit a long-term complete response for years [11,
19]. These observations are remarkable in light of the low and short-lived response rates
after  chemotherapy and currently  drive the development  of  adoptive T cell  therapy for
treatment of late stage melanoma.
The  development  of  adoptive  cell  therapy  (ACT)  was  further  strengthened  by  upcom‐
ing  technologies  in  isolating  tumor  infiltrating  lymphocytes  (TIL's)  from  melanoma  bi‐
opsies  (Figure  1).  First  described  in  1969  [20],  TIL's  from  melanoma  lesions  consisted
of  both effector  and helper  T cell  subsets  and can be expanded ex  vivo  in  the  presence
of  IL-2.  The  expanded cells  are  then selected for  melanoma reactivity.  A strong ration‐
ale  for  using  these  T  cells  in  adoptive  therapy is  provided by  the  observation  that  the
infusion  of  high  TIL  numbers  correlates  with  better  clinical  outcome  [21,  22]  although
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the  prevalence  of  TIL's  in  primary  melanoma lesions  and metastases  is  not  a  prognos‐
tic  factor  itself.
Protocols according to GMP standards have been established in several centers to isolate
and amplify TIL's to numbers appropriate for adoptive therapy. Melanoma reactive T cells
are expanded in the presence of IL-2 by culture on feeder cells expressing melanoma anti‐
gens [23]. Subsequent to TIL re-infusions, metastases regressed in the majority of patients
and a stable disease phase followed. However, only few patients remained in complete re‐
mission [21]. The disappointing therapeutic efficacy, despite high numbers of infused TIL's
is thought to be due to low responsiveness of highly expanded T cells which are unable to
execute a productive anti-melanoma attack after administration to the patient. Current TIL
protocols therefore attempt to administer so-called “young TIL's” (Figure 1), i.e. melanoma
infiltrating T cells which underwent short-term culture expansions and therefore passed
through fewer cell division cycles prior to re-infusion and thereby exhibit a less differentiat‐
ed phenotype [24]. Another change in protocols is that TIL's are not selected for melanoma
reactivity; the rationale behind this is that re-infusion of ex vivo IFN-γ secreting TIL's exhibit‐
ed no major benefit compared to non-responding TIL's [16]. Early phase I trials showed im‐
proved persistence of young TIL's [25] and 50% response rates in a cohort of 20 patients [26],
which is just as effective as traditionally grown TIL's [27]. Different non-randomized phase
II trials at the NCI and at Sheba Medical Center confirmed these early observations (Table 1)
[28, 29]. A roadmap describing critical steps for comparative testing the TIL strategy in a
randomized multi-center setting was recently published in a White Paper on adoptive cell
therapy [30].
Figure 1.  Adoptive  cell  therapy  for  metastatic  melanoma.  Adoptive  cell  therapy  with  tumor  infiltrating  lympho‐
cytes (TIL´s) makes use of melanoma-specific TIL´s which are isolated from a melanoma biopsy, amplified ex vivo
by stimulation with melanoma biopsy cells and propagated to high numbers in the presence of IL-2. In more re‐
cent  trials,  TIL´s  are  propagated short-term ex  vivo  without  stimulation  by  melanoma cells  and administered as
"young" TIL´s.
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Target antigen Adoptively transferred T cells NCT ID / Reference Center
melanoma specific CD8+ T cells [118] FHCRC
melanoma specific T cells [119] LUMC
MART-1 MART-1 specific CD8+ T cells [113] DFCI
MART-1 MART-1 specific CD8+ T cells NCT00512889 DFCI
MART-1 MART-1 specific CD8+ T cells [87] UR
MART-1 MART-1 specific CD8+ T cells [33] UNH
MART-1 MART-1 specific CD8+ T cells NCT00324623 CHUV
MART-1 MART-1 specific CD8+ T cells NCT01106235 FHCRC
NY-ESO-1 NY-ESO-1 specific CD8+ T cells and anti-CTLA-4 antibody NCT00871481 FHCRC
TILs [114] NIH
TIL [120] NIH
TILs [27] NIH
TILs [29] NIH
TILs [115] NIH
TILs NCT00287131 SMC
TILs NCT000604136 HMO
TILs NCT01005745 MOFFITT
TILs and IFN-γ NCT01082887 NUH
“young“ TILs [116] NIH
“young“ TILs [28] SMC
“young“ TILs NCT01118091 NIH
“young“ TILs NCT01319565 NIH
“young“ TILs NCT01369888 MIH
“young“ TILs NCT01468818 NIH
“young“ TILs NCT00513604 NIH
MART-1 MART-1 specific TILs NCT00720031 NUH
MART-1 MART-1 specific TILs (DMF5) NCT00924001 CC
IL-2 engineered TILs [117] NIH
IL-2 engineered TIL NCT00062036 NIH
IL-12 engineered TIL NCT01236573 NIH
CXCR2 engineered TIL [86] MDACC
NY-ESO-1 anti-NY-ESO-1 TCR [121] NIH
NY-ESO-1 anti-NY-ESO-1 TCR NCT00670748 NIH
MART-1 anti-MART-1 TCR (low-affinity) [49] NIH
MART-1 anti-MART-1 TCR NCT00910650 UC
MART-1 anti-MART-1 TCR (high-affinity) [38] NIH
gp-100 anti-gp-100 TCR [38] NIH
MART-1 anti-MART-1 TCR [114] NIH
gp-100 anti-gp-100 TCR [114] NIH
MART-1 anti-MART-1 TCR NCT00612222 NIH
gp-100 anti-gp-100 TCR NCT00610311 NIH
MART-1 anti-MART-1 TCR plus MART-1 vaccination NCT00923195 NIH
gp-100 anti-gp-100 TCR plus gp-100 vaccination NCT00923195 NIH
p53 anti-p53 TCR NCT00393029 NIH
VEGFR2 anti-VEGFR2 CAR engineered CD8+ T cells NCT01218867 NIH
Ganglioside GD-3 anti-GD-3 CAR PI: M. Davies MDACC
CHUV, Centre Hospitalier Universitaire Vaudois; DFCI, Dana-Farber Cancer Institute; FHCRC, Fred Hutchinson Cancer Research Center;
HMO, Hadassah Medical Organization; LUMC, Leiden University Medical Center; MDACC, M.D. Anderson Cancer Center; MOFFITT, H. Lee
Moffitt Cancer Center and Research Institute; NIH, National Institutes of Health; NUH, Nantes University Hospital; PI, principal investigator;
SMC, Sheba Medical Center; UC, University of California; UR, University of Regensburg
Table 1. Adoptive cell therapy trials in patients with metastatic melanoma
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3. Adoptive cell therapy with antigen-specific T cells
The rationale for using melanoma antigen-specific T cells is based on the observation that
the success of TIL therapy in some patients correlates with the presence of melanoma-reac‐
tive T cells, in particular with those cells specific for Melan-A, MART-1 or gp100 [23, 31].
The median survival of patients treated with Melan-A specific TIL's was 53.5 months com‐
pared to 3.5 months for patients who received TIL's without Melan-A specificity [32]. These
observations together with a number of technical obstacles in obtaining TIL's from biopsies
strengthened efforts to derive melanoma-specific T cell clones from peripheral blood lym‐
phocytes for the use in adoptive cell therapy. The strategy was corroborated by a 50% re‐
sponse rate obtained after transfer of MART-1 or gp100 specific T cell clones isolated and
propagated ex vivo from peripheral blood lymphocytes (Table 1) [33]. Melanoma reactive T
cell clones in peripheral blood are rare, TIL therapy increases the otherwise low magnitude
of the tumor-reactive T cell compartment in vivo, which matches the reactivity in the TIL
product [34]. Interestingly, individual TIL products from different patients contain unique
patterns of reactivity against shared melanoma-associated antigens [34]. TIL isolation and
expansion in vitro, however, is extremely laborious. This limit leads to attempts to engineer
patient's blood T cells with pre-defined specificity for more specifically redirecting the cyto‐
toxic response toward melanoma. It is therefore assumed that the clinical efficacy of TIL
therapy can be improved by application of T cells with more defined tumor-reactivity.
To engineer specificity for melanoma, T cell receptors (TCR's) were cloned from TIL's of re‐
sponding melanoma patients and transferred to peripheral blood T cells of the same patient
(Figure 2) [35-38]. The gp100 specific TCR was one of the first TCR’s, cloned from melanoma
TIL's and introduced ex vivo by retrovirus-mediated gene transfer into blood T cells, which
thus obtained redirected specificity for gp100 positive cells. In contrast to their non-modified
counterparts, TCR engineered T cells responded to gp100+ melanoma cells by secreting pro-
inflammatory cytokines including IFN-γ and by lysing the target cells [45, 46]. Similarly,
blood T cells were engineered with recombinant TCR’s with specificity for MART-1 or
MAGE-A1. The functional avidity of cloned TCR's was improved and engineered T cells
were successfully used in subsequent trials [47, 48]. About 30% of patients receiving ACT
with MART-1 specific T cells responded with melanoma regression; 19% of patients treated
with gp100 specific TCR T cells exhibited objective response, most responses were persistent
[38]. TCR engineered T cells also showed efficacy towards brain metastases, which indicates
that patients with otherwise incurable metastatic sites may benefit from ACT (Table 1) [115].
In patients with prolonged clinical remission, engineered T cells were present in the circula‐
tion for more than a year after initiation of treatment; this indicates that therapeutic efficacy
and long-term anti-melanoma immunity may correlate with T cell persistence [49, 50].
However, the enthusiasm for adoptive cell therapy with TCR modified T cells has been
dampened by several limitations. Tumor cells including those of the melanoma undergo clo‐
nal evolution, and some of these evolved cells evade T cell recognition, for instance, as a re‐
sult of repression of their MHC complex [51], of mutations in their β2 microglobulin chain
[52], and of deficiencies in their antigen processing machinery [51, 53]. Each of these altera‐
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tions renders the melanoma cell invisible to a TCR-mediated T cell attack. A possible safety
hazard moreover became apparent when analyzing in more detail the transgenic TCR,
which is co-expressed with the physiological TCR in the same T cell. The transgenic TCR
turned out to create new but unpredictable specificities by forming hetero-dimers of the re‐
combinant α and β TCR chains with the respective chains of the physiological TCR. Unde‐
sirable mispairing of TCR chains may result in loss of specificity and may induce severe
auto-reactivity [54, 55]. Tremendous efforts were subsequently made to solve the problem
including replacement of TCR constant moieties by the homologous murine domains [56]
and creation of additional cysteine bridges [57] to enforce preferential pairing of the re‐
combinant αβ TCR chains in the presence of the physiological TCR.
These and other technical difficulties promoted the development of an artificial “one-chain-
receptor” molecule to redirect T cells in an antigen-restricted manner (Figure 3). In a seminal
paper Zelig Eshhar of the Weizmann Institute of Science described a chimeric antigen recep‐
tor (CAR), also named immunoreceptor, which is composed in the extracellular part of a sin‐
gle chain antibody for antigen binding and in the intracellular part of the TCR/CD3ζ
endodomain for provision of T cell activation [58]. The CAR modified T cell, also known as
“T-body”, becomes activated by binding to antigen, and secretes pro-inflammatory cyto‐
kines, amplifies and lyses target cells expressing the respective antigen. By using an anti‐
body for binding, the CAR recognizes the target in a MHC-independent fashion and is
therefore not affected by loss of HLA molecules, which frequently occurs during neoplastic
Figure 2. Adoptive cell therapy with redirected T cells. T cells from the peripheral blood of the patient are engi‐
neered ex vivo by retro- or lentiviral gene transfer with cDNA coding for a T cell receptor (TCR) with specificity for a
melanoma-associated antigen. Alternatively, T cells are engineered with a chimeric antigen receptor (CAR) which rec‐
ognizes a melanoma-associated antigen by an antibody-derived binding domain. Engineered T cells are expanded ex
vivo prior to administration to the patient.
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progression. An additional advantage over transgenic TCR's is that CAR's can be used inde‐
pendently of the individual HLA subtype. However, the T-body strategy is restricted to an‐
tigens expressed on the surface of the target cell; intracellular antigens are not visible to
CAR's. Due to the broad variety of antibodies available, a nearly unlimited panel of antigens
can be targeted with high affinity and specificity, including those which are not classical T
cell antigens, e.g. carbohydrates. High affinity CAR's activate engineered T cells even after
binding to low amounts of target antigen; this not only makes the approach highly sensitive,
but also makes the choice of the appropriate melanoma-selective antigen difficult.
Figure 3. Recombinant receptors to redirect T cells for use in antigen-specific cell therapy. The physiologic T cell
receptor (TCR)/CD3 complex consists of the α and β TCR chains, which recognize major histocompatibility complex
(MHC)-presented antigen by binding through both variable regions Vα Vβ, and of the CD3 chains. Antigen engage‐
ment induces clustering of the TCR complex and the primary signal for T cell activation is generated by the intracellu‐
lar CD3ζ chain. Recombinant TCR α and β chains can be engineered to T cells in order to provide a new specificity.
Alternatively, the V regions of the TCR chains can be combined and fused to the intracellular CD3ζ chain to produce a
T cell activation signal upon binding to antigen. The chimeric antigen receptor (CAR) makes use of an antibody bind‐
ing domain for antigen recognition which is enigneered by fusing the variable (V) regions of the immunoglobulin
heavy (H) and light (L) chain. The VH-VL single chain antibody is linked via a spacer to the intracellular CD3ζ chain to
produce the primary T cell activation signal upon antigen binding. Intracellular signaling domains of costimulatory
molecules like CD28 can be added to provide appropriate costimulation in addition to the primary CD3ζ signal.
T cells require two signals for full and lasting activation, one provided by the TCR and the
other by costimulatory co-receptors; the prototype of which is CD28. The corresponding li‐
gands are usually not present in the tumor micro-environment. Some effector functions in‐
cluding IL-2 secretion require CD28 costimulation along with the primary TCR/CD3ζ signal;
this provides a rationale for combining the intracellular CD3ζ with the CD28 signaling do‐
main in one polypeptide chain (Figure 3) [59]. Other costimulatory domains, such as 4-1BB
(CD137) and OX40 (CD134), were also linked to CD3ζ; each domain has a different impact
on T cell effector functions [60]. Costimulatory domains were furthermore combined in so-
called 3rd generation CAR's, and a number of additional modifications have been intro‐
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duced in the last years to improve T cell persistence and activation [61, 62]. CAR's with a
costimulatory domain clearly demonstrated clinical benefit and improved T cell persistence
compared to CAR's targeting the same antigen but with only the CD3ζ domain [63-65].
Various CARs were engineered for targeting melanoma-associated antigens, including
HMW-MAA, also known as MCSP [67, 68], melanotransferrin [69], the ganglioside GD2 [70]
and GD3 [71]. A clinical trial targeting melanoma cells with CAR engineered T cells is cur‐
rently recruiting participants [66]. Recent phase I trials using CAR redirected T cells in the
treatment of lymphoma/leukemia exhibited spectacular efficacy [72, 73]. However, the en‐
thusiasm was dampened by reports on serious adverse events and even fatalities after CAR
T cell therapy [74, 75]. Targeting ErbB2 produced a cytokine storm and respiratory failure in
one case [76] which is thought to be due to low levels of antigen on a number of healthy
cells which can trigger CAR T cell activation. On the one hand, this event points out that
ACT with CAR modified T cells may be a powerful therapy; but, on the other hand, empha‐
sizes the necessity for careful T cell dose escalation studies to balance anti-tumor efficacy
and auto-immunity[61, 77, 78].
4. Challenges and premises in the adoptive cell therapy of melanoma
To date, approximately half of the melanoma patients treated with TIL ACT benefit from
this therapy; genetic modification of T cells may further improve clinical response to mela‐
noma, but this will have to be proven in upcoming trials. However, the strategy has poten‐
tial challenges which need to be addressed.
A major challenge of redirected T cells is the tumor selectivity for the target antigen itself,
which in most cases is not exclusively expressed on tumor cells but also on healthy cells [79],
although almost always at lower levels: for instance MART-1, which is also expressed by
melanocytes. When targeting these antigens, vitiligo and inner ear toxicity resulting in a cer‐
tain degree of deafness are frequently observed side effects [38]. From this perspective it is
reasonable to assume that off-target toxicities may be adverse reactions for clinical efficacy
in an anti-melanoma response [80]. Since nearly all tumor-associated antigens are self-anti‐
gens, strategies will have to be developed to ensure that off-target toxicities are kept to a
minimum. Whether T cells with low-avidity TCR or CAR are less prone to induce such un‐
desirable side effects is currently under investigation.
Melanoma cells, like other cancer cells, down-regulate components of the MHC and become
increasingly deficient in antigen processing. As a consequence, TCR engineered T cells can
no longer bind to and destroy those melanoma cells. However, they may be visible to a CAR
recognizing surface antigens in a MHC independent manner, because of the antibody-de‐
rived binding domain (Figure 3). TCR redirected T cells, on the one hand, may also recog‐
nize cross-presented targeted antigen, for instance by stroma cells, but this is not the case for
CAR engineered T cells. Cross-presented antigen, on the other hand, may help to destroy
stroma, which is required to eliminate large tumor lesions [39, 40].
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To avoid mispairing of the recombinant TCR with the physiological TCR chains and the re‐
sulting unpredictable auto-immunity, TCR-like single chain antibodies were used as target‐
ing domain in a CAR. Thus combining the MHC-restricted recognition of antigen with the
T-body strategy. T cells with TCR-like CAR were redirected towards NY-ESO-1 and MAGE-
A1, respectively [41, 42]. The possible advantages of these MHC restricted CAR's compared
to the use of recombinant TCR's still has to be determined in trials.
The antibody-derived binding domain of a CAR displays extraordinary high affinity com‐
pared to a TCR. However, an increase in affinity, for instance, by affinity maturation, does
not necessarily improve CAR redirected T cell activation above threshold [41, 43], which is
not additionally modulated by CD28 costimulation [44]. A similar effect is also assumed for
TCR mediated T cell activation. The TCR or CAR binding avidity probably affects the persis‐
tence of engineered T cells at the targeted tumor site. Strong binding to a target antigen may
cause the T cells to be trapped and to become fully activated for a cytolytic attack, whereas
low avidity interactions may not provide sufficiently long T cell – melanoma cell contacts. In
addition to the binding avidity, the amount of target antigen on the cell surface also impacts
on the selectivity of redirected T cell activation. In essence, low affinity binding directs the
activity of engineered T cells preferentially toward target cells with abundant antigen levels;
high affinity binding is likewise effective against low antigen levels on target cells. The opti‐
mized affinity to sustain a more selective T cell trafficking to the tumor and activation while
avoiding targeting healthy cells that are expressing low quantities of the same antigen, how‐
ever, still has to be determined.
A beneficial T cell-to-target cell ratio at the tumor site seems to be required for efficient tu‐
mor elimination. Higher numbers of engineered T cells applied per dose will probably in‐
crease clinical efficacy; the majority of recent trials have applied up to 1010 cells per dose
[27]. These and higher numbers of engineered T cells can be generated by extended expan‐
sion protocols; however, cells with a "young" phenotype may not be generated for adoptive
transfer under these conditions. Short-term amplification protocols are therefore envisioned
for both TIL's and engineered blood T cells. However, the majority of recent trials targeting
CD19+ leukemia provided evidence for therapeutic efficacy at numbers less than or equal to
105 engineered T cells [73]. This once again raises the question of whether high T cell doses
are required for a therapeutic effect.
The clinical outcome of adoptive cell therapy correlates with the persistence of adoptively
transferred T cells [81]. As long as T cells engage their cognate antigen, T cells will expand
and persist in detectable numbers; but when the antigen is no longer present, the T cell pop‐
ulation will contract to potentially undetectable levels and disappear from circulation. To
improve survival of CAR T cells, Epstein-Barr virus (EBV)-specific T cells were engineered
with a tumor-specific CAR based on the rationale that T cells recognizing the low amounts
of EBV antigens by their physiological TCR will be maintained in a sizable population in cir‐
culation and in the process providing enough CAR T cells to recognize and kill melanoma
cells in the surrounding tissues. A clinical trial with EBV-specific T cells engineered with an
anti-GD2 CAR thus showed benefit over non-virus-specific, CAR engineered T cells in the
treatment of neuroblastoma [81].
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Adoptively transferred CD8+ T cell clones may be less persistent than CD4+ T cell clones due
to T cell exhaustion after extensive ex vivo amplification and multiple rounds of activation.
In addition, CD4+ T cell help is essential for CD8+ T cell persistence in vivo; adoptively trans‐
ferred pure CD8+ T cell clones may fail to persist [82]. T cell therapy may be combined with
antibody therapy to prolong the initiated immune response. For instance, CTLA-4 is upre‐
gulated on the surface of activated T cells, where it acts as negative regulator to return the T
cell to a resting stage. Co-application of the anti-CTLA-4 blocking antibody, ipilimumab,
may prolong the anti-tumor activation of transferred T cells, although it would also affect all
the other T cells.
Besides maintaining a high number of T cells in circulation, another challenge is to accumu‐
late significant numbers of effector T cells in the tumor lesion. A tightly controlled network
of chemokines controls the migration of cells in the body; adoptively transferred T cells use
these networks to accumulate at the tumor site. The expression of specific chemokine recep‐
tors controls how cells will migrate against the chemokine gradient into the targeted lesion.
Melanoma cells secrete a number of chemokines including CXCL1. However, early imaging
studies revealed that melanoma-specific T cells massively infiltrate the lungs, spleen and liv‐
er with some accumulation at the tumor site, which clearly represents a minority of the
transferred cells, before the cells decline to undetectable levels in circulation [83-85]. Since
those T cells do not express CXCR2, the receptor for melanoma secreted CXCL1, TIL's were
engineered with CXCR2 which generated improved melanoma accumulation and anti-tu‐
mor activity in a mouse model [86]. The strategy is currently being explored in an early
phase I trial (Table 1) [86].
One of the major hurdles of redirected immunotherapy of cancer in general is the tremen‐
dous heterogeneity of cancer cells with respect to the expression of the targeted antigen.
Low or lack of antigen expression within the malignant lesions will negatively affect the
long-term therapeutic efficacy of the approach. Several reports document relapse of anti‐
gen-loss  tumor  metastases  after  adoptive  therapy  with  melanoma-reactive  T  cell  clones
[87-89]  and argue for  the  use  of  polyclonal  T  cells  with  various  melanoma specificities.
Melanoma cells expressing the target antigen may successfully be eliminated by redirect‐
ed T cells, whereas antigen-negative tumor cells will not be recognized. T cell populations
modified with different  CAR's  recognizing different  antigens expressed by the same tu‐
mor may be able to overcome these limitations. However, pro-inflammatory cytokines se‐
creted by redirected T cells into the tumor micro-environment upon activation may attract
a second wave of non-antigen restricted effector cells, which in turn may eradiate antigen-
negative tumor cells. At least in an animal model, antigen-negative melanoma cells are in‐
deed eliminated when co-inoculated with antibody-targeted cytokines  [90].  Moreover,  T
cells engineered with induced expression of transgenic IL-12 attract innate immune cells
including macrophages into the tumor tissue; they eliminate antigen-negative tumor cells
in the same lesion [91].
Highly expanded T cells, such as TIL's, become hypo-responsive to CD28 costimulation and
rapidly enter activation induced cell death, in particular upon IL-2 driven expansion [92].
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This may be counteracted by expansion in the presence of IL-15 and IL-21 and/or by co-stim‐
ulation via 4-1BB by an agonistic antibody [93].
Metastatic melanoma patients with the B-raf activating mutation V600E transiently benefit
from a small molecule drug, PLX4032 or vemurafenib, which inhibits the mitogen-activated
protein kinase (MAPK) pathway. Treatment with vemurafenib is accompanied by increased
T cell infiltrations in the melanoma lesions [94, 95]. Combination of B-raf inhibition with
melanoma-specific ACT may provide an option to prolong the clinical response.
Although the TCR downstream signaling machinery is used by the prototype CAR, mono‐
cytes, macrophages as well as NK cells can also be redirected by CAR's in an antigen-spe‐
cific  fashion  [96,  97].  Whether  redirected  non-T  cells  are  advantageous  in  tumor
elimination to cancer patients in general and to melanoma patients in particular has to be
explored in clinical trials.
5. Does targeting "melanoma stem cells" provide hope for long-term
remission from melanoma?
Observations that a number of malignant lesions display a tremendous cellular and pheno‐
typic heterogeneity and contain pluripotent stem cells led to the hypothesis that cancer is
initiated and maintained by so-called cancer stem cells (CSC’s). Low abundance, induction
of tumors upon transplantation under limiting conditions, radiation and chemo-resistance,
self-renewal and a-symmetric differentiation into a variety of cell types are properties postu‐
lated for CSC’s. The concept was sustained by deciphering the hierarchical organization in
hematological malignancies [98], and subsequently in solid cancers including mammary,
prostate, pancreatic, colon carcinoma and glioma [99-103]. Transplantation of melanoma cell
subsets under limiting dilution conditions showed that a subset of cancer cells can induce
tumors of the same histological phenotype as the parental tumor [99, 104, 105]. A first study
using the limiting dilution transplantation assay identified a melanoma cell subset which ex‐
hibits stem-like capacities and expresses CD20 [106]. A conclusion drawn from these and
other experiments was that melanoma is organized in a hierarchical manner originating
from an initiator cell. In this context, several phenomena in melanoma biology which have
been clinically observed but not well understood are described by the CSC model, for in‐
stance, metastatic relapse more than a decade after surgical treatment of the primary lesion.
Residual CSC’s are thought to drive cancer relapse even after years of “dormancy” [107].
Moreover, melanoma initiating cells were identified as expressing either the transporter pro‐
tein ABCB5 [104] or the nerve growth factor receptor CD271; the latter occurs in melanoma
in a frequency of approximately 1/2000 cells [108].
However, transplantation under more rigorous conditions, i.e., ideally of one isolated mela‐
noma cell, revealed that nearly every fourth randomly taken melanoma cell (1/2 - 1/15) can
induce tumors and raising the question of the validity the stem cell paradigm for melanoma
[109, 110]. From these and subsequent studies, it has been concluded that the potential of
melanoma induction is not closely associated with a particular phenotype and that the num‐
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ber of potential CSC’s in melanoma may not necessarily be low. This resulted in a further
conclusion that nearly every melanoma cell is capable to re-program to a tumor initiating
cell under certain experimental conditions of xeno-transplantation irrespectively which par‐
ticular marker phenotype the cell expressed at the time of isolation from a melanoma lesion.
Once the tumor is established, a minor subset seems to take over control of melanoma progres‐
sion. Evidence is provided by recent observations from a pre-clinical model [69], which ad‐
dressed the question of whether specific  elimination of defined melanoma cells  from an
established xeno-transplanted lesion causes tumor regression by adoptive transfer of antigen-
specific cytotoxic T cell. The rationale is that, if there is a clearly defined hierarchy of cancer
cells in an established tumor, specific ablation of the melanoma sustaining cells from the estab‐
lished tumor tissue must inevitably lead to a decay of the tumor lesion independently of target‐
ing the cancer cell  mass.  However,  the melanoma sustaining cell  may, but must not,  be
identical to CSC’s identified by the transplantation assay. Targeted elimination of a minor sub‐
set of CD20+ melanoma cells completely eradicated transplanted melanoma lesions, whereas
targeted elimination of any random melanoma cell population in the same lesion did not.
CD20+ melanoma cells are rare, i.e. approximately 1-2%, in melanoma, independently of the
histological type and the transplanted tumor tissue. A caveat is that in approximately 20% of
melanoma samples, no CD20+ melanoma cells could be detected by histological screening.
When these tumors were transplanted, adoptive transfer of CD20-specific CAR T cells did not
induce tumor regression. Interestingly, CD20 re-expression in a random subpopulation of
those tumor cells did not render the tumor lesion sensitive for complete eradication with CD20-
specific T cells. This indicates that CD20 expression per se is not dominant in maintaining mela‐
noma progression. However, the phenotype of CD20+ melanoma cells may be flexible and
associated with additional capabilities which mediate the dominant effect.
The first clinical evidence confirming this concept was recently provided by a case report
[111]. A patient with stage III/IV metastatic melanoma, which harbored CD20+ melanoma
cells at a frequency of 2%, received intra-lesional injections of the anti-CD20 therapeutic an‐
tibody rituximab and concomitant dacarbazine treatment. Dacarbazine as mono-therapy
had already proved to be ineffective. This treatment produced lasting complete and partial
remission accompanied by a decline of the melanoma serum marker S-100 to physiological
levels, a switch of a T helper-2 to a more pro-inflammatory T helper-1 response, all without
treatment related grade 3/4 toxicity. Although anecdotic, this data provides the first clinical
evidence that targeting the subset of CD20+ melanoma sustaining cells can produce regres‐
sion of chemotherapy-refractory melanoma. Moreover, the report highlights the potency of
selective cancer cell targeting in the treatment of melanoma.
These observations although so far based on a pre-clinical model and a clinical observation
which will have to be reproduced in larger cohorts have major impact on the future devel‐
opment of melanoma therapy.
First, the melanoma maintaining cells may be more resistant to current therapy regimens
than the bulk of melanoma cells. Standard therapy strategies attempt to eliminated all can‐
cer cells in a tumor lesion; elimination of any other cancer cells than the tumor progressing
cells will rapidly de-bulk the tumor lesion. The melanoma will inevitably relapse, driven by
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the remaining melanoma sustaining cells, which are extraordinary resistant to chemothera‐
peutics. This resistance is probably due to transporter molecules like ABCB5, which are
highly expressed by a number of CSC’s including melanoma [104] and therefore efficiently
counteract chemotherapy. Melanoma maintaining cells like other CSC’s are merely in a
"dormant" state and replicate less frequently than the majority of cancer cells in the same le‐
sion, which reduces the efficacy of anti-proliferative drugs. Low proliferative capacities to‐
gether with the efficient export of chemotherapeutics contribute to CSC resistance toward a
variety of therapeutic drugs. As a consequence, alternative strategies that specifically induce
cell death of those cells are required. Moreover, the situation is exacerbated by the fact that
the melanoma maintaining cells in the lesion are rare and unlikely to be eliminated by the
random targeting provided by most therapeutic agents. Specific targeting by cytotoxic T
cells redirected towards CD20 or by CD20-specific therapeutic antibodies like Rituxan™ (rit‐
uximab) or Arzerra™ (ofatumumab), probably as adjunct to a tumor de-bulking strategy,
may improve the situation.
Second, whether the prevalence of CD20+ melanoma maintaining cells in a tumor lesion may
correlate with clinical progression or relapse has to be addressed. If so, the frequency of
CD20+ melanoma cells may serve as a surrogate marker for therapeutic efficacy and/or prog‐
nosis. Chemotherapy and/or radiation may induce amplification of these cells thus contribu‐
ting to their accumulation during tumor progression and metastasis.
Third, melanoma maintaining cells may exhibit an extraordinary functional and phenotyp‐
ic plasticity. As a consequence, continuous presence of targeting therapeutic agents will be
required  to  eliminate  those  cells,  which  exhibit  newly  acquired  melanoma  initiating
and/or  maintaining  capacities.  In  their  pre-clinical  model,  Schmidt  and  colleagues  [69]
used CAR engineered T cells which penetrate tissues, scan for targets and persist for long-
term acting as an antigen-specific guardian. These T cells are present in the targeted le‐
sion as long as cells expressing the target antigen appear. Repetitive restimulation of these
T cells, for instance by engaging their TCR with EBV-specific antigens [63, 81], may sus‐
tain persistence of  CAR T cells  in  sufficient  numbers  over long periods of  time.  In this
constellation, cellular therapy has a major advantage compared to pharmaceutical drugs,
which are present in therapeutic levels for short periods; in the case of melanoma the re‐
quired period for  screening for  re-appearance of  such melanoma initiating cells  may be
many years.  The  development  of  an  antigen-specific  memory  by  adoptively  transferred
CAR T cells, as recently shown in a pre-clinical model [112], may be of benefit to patients
in preventing a melanoma relapse.
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